Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Development Pipeline Vosaroxin Vosaroxin is a first-in-class anti-cancer quinolone derivative (AQD)—a class of compounds that has not been used previously for the treatment of cancer. The company licensed worldwide development and commercialization rights to vosaroxin from Dainippon Sumitomo Pharma Co., Ltd. in 2003. Vosaroxin acts by DNA intercalation and inhibition of topoisomerase II in replicating cancer cells. The resulting site-selective DNA damage rapidly causes the cancer cells to stop dividing and die. In preclinical studies, vosaroxin demonstrated broad anti-tumor activity and exhibited additive or synergistic activity when combined with therapeutic agents used in the treatment of cancer, including cytarabine. Clinical activity is observed in both solid and hematologic malignancies. MLN2480 MLN2480 is a pan-Raf kinase inhibitor with a distinct molecular signature which has exhibited a promising preclinical profile. SNS-062 SNS-062 is a potent, non-covalently binding inhibitor of BTK. BTK mediates signaling through the B-cell receptor, or BCR, which is critical for adhesion, migration, proliferation and survival of normal and malignant B-lineage lymphoid cells. Strategy The company plans to continue to build a leading biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers by: obtaining regulatory approval to market vosaroxin as a treatment for relapsed or refractory acute myeloid leukemia (AML) in the United States, Europe and other major markets; building a commercial infrastructure in order to promote and market vosaroxin in the United States and other major markets as a treatment for AML; leveraging potential partners and distributors to commercialize vosaroxin in selective international markets; establishing vosaroxin as the new standard of care for patients with relapsed or refractory AML; exploring the broader potential of vosaroxin, beyond pivotal indication, in different patient segments within AML and MDS through investigator sponsored studies; investing in additional clinical testing to evaluate vosaroxin for additional AML indications, MDS, other hematologic malignancies and solid tumors; leveraging strong intellectual property protection over vosaroxin in order to expand the vosaroxin program beyond its lead AML indication; supporting multi-kinase inhibitor programs with Millennium in oncology and Biogen Idec for immunology indications; conducting IND-enabling studies for BTK inhibitor, SNS-062, with a view to commencing human clinical trials for this compound in 2015; conducting preclinical work on in-licensed PDK1 inhibitor program with the goal of selecting a lead PDK1 development candidate to take into IND-enabling studies in 2014; continuing to expand and develop oncology-focused pipeline through further licensing or collaboration arrangements and research and development; and investing in internal discovery programs for the development of novel small molecule therapeutics. Collaboration Agreements The company has license and collaboration agreements with Biogen Idec and Millennium Pharmaceuticals, Inc. In January 2014, the company announced the expansion of oncology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec MA, Inc., or Biogen Idec, is for global commercial rights to SNS-062, a potent and selective non-covalently binding oral inhibitor of Bruton’s tyrosine kinase, or BTK. The second agreement, with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, is for global commercial rights to potential first-in-class, pre-clinical inhibitors of the novel target phosphoinositide-dependent kinase-1, or PDK1. Intellectual Property The original vosaroxin composition of matter is covered by U.S. Patent No. 5,817,669 and its counterpart patents in 43 foreign jurisdictions. This U.S. patent would expire in October 2015, while its foreign counterparts would expire in June 2015. As of December 31, 2013, the company owned, co-owned or had rights to approximately 133 granted U.S. and foreign patents, and approximately 124 pending U.S. and foreign applications, pertaining to vosaroxin and compositions and uses thereof. Research and Development The company incurred $28.9 million of research and development expenses in 2013 primarily related to the development of vosaroxin. History The company was founded in 1998. It was incorporated in the state of Delaware in 1998.
sunesis pharmaceuticals inc
395 Oyster Point Boulevard
South San Francisco, CA 94080
|NeurogesX Inc||$0.0090 USD||0.00|
|POZEN Inc||$7.80 USD||-0.26|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.